Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer

NCT00181584 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Bone Loss
Prostate Cancer

Interventions

DRUG: Zoledronic acid
OTHER: Placebo

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]